CA3231813A1 - Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds - Google Patents

Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds Download PDF

Info

Publication number
CA3231813A1
CA3231813A1 CA3231813A CA3231813A CA3231813A1 CA 3231813 A1 CA3231813 A1 CA 3231813A1 CA 3231813 A CA3231813 A CA 3231813A CA 3231813 A CA3231813 A CA 3231813A CA 3231813 A1 CA3231813 A1 CA 3231813A1
Authority
CA
Canada
Prior art keywords
compound
solid form
pharmaceutical composition
amount
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3231813A
Other languages
English (en)
French (fr)
Inventor
Sibao CHEN
Christopher COOPER G. F.
Baudouin Gerard
Joshua Courtney Horan
Jason T. Kropp
Benjamin Stephen Lane
David James Pearson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvalent Inc
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of CA3231813A1 publication Critical patent/CA3231813A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3231813A 2021-10-01 2022-09-30 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds Pending CA3231813A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251514P 2021-10-01 2021-10-01
US63/251,514 2021-10-01
PCT/US2022/077323 WO2023056405A1 (en) 2021-10-01 2022-09-30 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Publications (1)

Publication Number Publication Date
CA3231813A1 true CA3231813A1 (en) 2023-04-06

Family

ID=84044639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3231813A Pending CA3231813A1 (en) 2021-10-01 2022-09-30 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds

Country Status (11)

Country Link
US (2) US12043626B2 (https=)
EP (1) EP4408844A1 (https=)
JP (1) JP2024537795A (https=)
KR (1) KR20240087788A (https=)
CN (1) CN118234725A (https=)
AU (1) AU2022357554A1 (https=)
CA (1) CA3231813A1 (https=)
IL (1) IL311444A (https=)
MX (1) MX2024003738A (https=)
TW (1) TW202320768A (https=)
WO (1) WO2023056405A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CA3231608A1 (en) * 2021-10-01 2023-04-06 Amit M. Deshpande Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
WO2024036097A1 (en) 2022-08-12 2024-02-15 Nuvalent, Inc. Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2025131085A1 (zh) * 2023-12-22 2025-06-26 首药控股(北京)股份有限公司 一种新型激酶抑制剂
WO2025212478A1 (en) 2024-04-01 2025-10-09 Nuvalent, Inc. Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2026026817A1 (zh) * 2024-07-29 2026-02-05 海南先声再明医药股份有限公司 大环类alk抑制剂、其制备方法和用途

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
JPS60243083A (ja) 1984-05-18 1985-12-03 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体、その製法および該誘導体を含有する除草剤
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5569655A (en) 1993-09-14 1996-10-29 Sterling Winthrop Inc. Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5849735A (en) 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
ATE335050T1 (de) 2000-12-20 2006-08-15 Kyowa Hakko Chemical Co Ltd Squaryliumverbindungen vom metallkomplex-typ sowie optische aufzeichnungsmedien hergestellt unter verwendung derselben
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
AU2003268752A1 (en) 2002-10-30 2004-05-25 Sumitomo Chemical Company, Limited High-molecular compounds and polymerer light emitting devices made by using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
EP1756072A2 (en) 2004-04-27 2007-02-28 Wyeth Purification of progesterone receptor modulators
TW200604137A (en) 2004-04-27 2006-02-01 Wyeth Corp Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US7445211B1 (en) 2005-03-11 2008-11-04 Walton Daniel J Wall decoration and game apparatus
US20070116984A1 (en) 2005-09-21 2007-05-24 Doosan Corporation Spiro-compound for electroluminescent display device and electroluminescent display device comprising the same
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
GB0526044D0 (en) 2005-12-21 2006-02-01 Syngenta Ltd Novel herbicides
PT1988779E (pt) 2006-02-16 2015-09-04 Anacor Pharmaceuticals Inc Moléculas pequenas contendo boro como agentes antiinflamatórios
GB0603891D0 (en) 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
US20070213526A1 (en) 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US7915414B2 (en) 2006-11-24 2011-03-29 Yun Chi Blue-emitting organometallic complexes and their application
FR2913882B1 (fr) 2007-03-20 2009-05-01 Oreal Utilisation pour la coloration des fibres keratiniques d'une composition comprenant un compose halochromique et/ou le colorant correspondant a ce compose
KR20100033484A (ko) 2007-06-26 2010-03-30 사노피-아벤티스 어닐링된 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 금속 촉매된 합성
CN101784553A (zh) 2007-07-02 2010-07-21 阿斯利康(瑞典)有限公司 3-螺嘧啶三酮-喹啉衍生物及其作为抗菌药物的应用
US10189803B2 (en) 2008-02-22 2019-01-29 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
KR20150065941A (ko) 2008-03-06 2015-06-15 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
JP2009234928A (ja) 2008-03-25 2009-10-15 Kyoto Univ 縮合多環芳香族化合物、およびその製造方法
JP5304010B2 (ja) 2008-04-23 2013-10-02 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
JP5499519B2 (ja) 2009-05-27 2014-05-21 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
MX2012001414A (es) 2009-08-04 2012-03-26 Tokuyama Corp Compuesto de cromeno.
JP4599469B1 (ja) 2009-08-31 2010-12-15 富士フイルム株式会社 有機電界発光素子用材料及び有機電界発光素子
US8410091B1 (en) 2009-09-11 2013-04-02 Boehringer Ingelheim International Gmbh Process for preparation of substituted 2-amino-5-(5-(heterocyclemethyl)pyridin-2-yloxy)benzoic acid
US20110071136A1 (en) 2009-09-16 2011-03-24 Cylene Pharmaceuticals, Inc Novel tricyclic protein kinase modulators
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
WO2012016147A2 (en) 2010-07-30 2012-02-02 Dr. Reddy's Laboratories Ltd. Ligands for selective asymmetric hydroformylation
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
JP2013544277A (ja) 2010-12-01 2013-12-12 ファイザー・インク Ｋａｔｉｉ阻害剤
ES2559519T3 (es) 2010-12-22 2016-02-12 Université Catholique de Louvain Nuevos derivados de fenazina y su uso
FR2969611B1 (fr) 2010-12-28 2013-02-08 Sanofi Aventis Nouveaux derives de thiazoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
US9133168B2 (en) 2010-12-28 2015-09-15 Sanofi Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2012102409A1 (ja) 2011-01-27 2012-08-02 株式会社トクヤマ クロメン化合物
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
CN102408385B (zh) 2011-06-20 2014-06-18 雅本化学股份有限公司 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US9518217B2 (en) 2011-09-06 2016-12-13 E Ink Holdings Inc. Transition metal carbene complexes and the electroluminescent application thereof
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
CN102603659B (zh) 2012-03-01 2014-03-26 雅本化学股份有限公司 1-取代-4-溴-1h-1,2,3-三氮唑-5-羧酸及其制备方法
DK2822953T5 (en) * 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
KR20140032823A (ko) 2012-09-07 2014-03-17 롬엔드하스전자재료코리아유한회사 유기 전계 발광 소자
JP6199752B2 (ja) 2013-01-24 2017-09-20 出光興産株式会社 有機エレクトロルミネッセンス素子用材料及びそれを用いた有機エレクトロルミネッセンス素子、並びに含窒素複素環化合物
WO2014138912A1 (en) 2013-03-13 2014-09-18 Queen's University At Kingston Luminescent compounds and methods of using same
CA2916605C (en) 2013-06-28 2018-04-24 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
ES2792979T3 (es) 2013-08-22 2020-11-12 Jubilant Biosys Ltd Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos
KR102100929B1 (ko) 2013-09-04 2020-04-14 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US20160256448A1 (en) 2013-11-18 2016-09-08 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
KR102167048B1 (ko) 2013-12-03 2020-10-19 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
WO2015104711A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
KR102191992B1 (ko) 2014-01-22 2020-12-17 삼성디스플레이 주식회사 유기 발광 소자
KR102253441B1 (ko) 2014-03-10 2021-05-20 삼성디스플레이 주식회사 화합물 및 이를 포함한 유기 발광 소자
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
KR101793335B1 (ko) 2014-09-30 2017-11-02 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
CN105585534B (zh) 2014-10-23 2018-05-18 上海雅本化学有限公司 一种1-取代-1h-1,2,3-三氮唑-4-羧酸的制备方法
US20160140491A1 (en) 2014-11-17 2016-05-19 Gregory Forgatch System and method for integrating intermediary and end-user online retail experiences
EP4234017B1 (en) 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
US9887372B2 (en) 2015-06-11 2018-02-06 Samsung Display Co., Ltd. Amine-based compound and organic light-emitting device including the same
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
WO2017080980A1 (en) 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
CA3004680A1 (en) 2015-11-13 2017-05-18 Mavalon Therapeutics Limited Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
PL3380479T3 (pl) 2015-11-25 2023-05-08 Gilead Apollo, Llc Triazolowe inhibitory acc i ich zastosowania
CN105669733A (zh) 2016-01-29 2016-06-15 上海毕路得医药科技有限公司 一种1-甲基-1h-吡唑-3-硼酸频哪醇酯的合成方法
WO2017148325A1 (zh) 2016-03-03 2017-09-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN106243096B (zh) 2016-07-29 2019-11-29 上海璃道医药科技有限公司 三环类药物的新用途
JP6798851B2 (ja) 2016-10-14 2020-12-09 株式会社トクヤマ クロメン化合物、及び該クロメン化合物を含む硬化性組成物
WO2018111803A1 (en) 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
CN109528717B (zh) 2017-09-21 2021-08-17 中国科学院分子细胞科学卓越创新中心 治疗或预防肥胖或其相关疾病的化合物及其应用
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20210283261A1 (en) 2017-12-05 2021-09-16 Icahn School Of Medicine At Mount Sinai Compositions and Methods for Treating ALK-Mediated Cancer
US11680059B2 (en) 2017-12-21 2023-06-20 Guangzhou Chinaray Optoelectronic Materials Ltd. Organic mixture and application thereof in organic electronic devices
EP3750909B1 (en) 2018-02-11 2025-03-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN111356689B (zh) 2018-02-21 2023-11-10 株式会社Lg化学 化合物及包含其的有机发光器件
KR102192368B1 (ko) 2018-02-28 2020-12-17 주식회사 엘지화학 유기 발광 소자
CN110357905B (zh) 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
CN108912175A (zh) 2018-06-05 2018-11-30 长春海谱润斯科技有限公司 一种金属铱配合物及其有机发光器件
JP7377266B2 (ja) 2018-07-26 2023-11-09 アントローム マンノース誘導体の製造方法
US10593889B1 (en) 2018-09-26 2020-03-17 Idemitsu Kosan Co., Ltd. Compound and organic electroluminescence device
AU2019348006A1 (en) 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
AU2019373203B2 (en) 2018-10-30 2024-10-24 Bristol-Myers Squibb Company Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha
CN109912433B (zh) 2019-03-07 2022-04-08 石家庄诚志永华显示材料有限公司 化合物、有机电致发光材料、有机电致发光器件、电子装置
KR20200111577A (ko) 2019-03-19 2020-09-29 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP3844166B1 (en) 2019-05-14 2023-07-12 Teligene Ltd Substituted macrocycles useful as kinase inhibitors
US20220298130A1 (en) 2019-08-02 2022-09-22 Duk San Neolux Co., Ltd. Organic electronic device
CN112321604A (zh) 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
GB201913756D0 (en) 2019-09-24 2019-11-06 Chromatwist Ltd Contrast agent
US20220402948A1 (en) 2019-09-26 2022-12-22 Betta Pharmaceuticals Co., Ltd. Egfr inhibitor, composition and preparation method therefor
WO2021062327A1 (en) 2019-09-27 2021-04-01 Jubilant Biosys Limited Fused pyrimidine compounds, compositions and medicinal applications thereof
CN110734456A (zh) 2019-11-06 2020-01-31 南京谷睿生物科技有限公司 一种化合物及其制备方法和医药上的应用
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN112812128B (zh) 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
AU2020409909B2 (en) 2019-12-16 2024-03-14 Sogang University Research & Business Development Foundation Novel transition metal electron transfer complex having C-N ligand and electrochemical bio sensor using same
TW202136246A (zh) 2019-12-19 2021-10-01 德商麥克專利有限公司 電子裝置用化合物
CN113121607B (zh) 2019-12-31 2023-07-04 马鞍山南大高新技术研究院有限公司 一种主配体含喹啉/喹唑啉的红光铱配合物与应用
BR112022019517A2 (pt) 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
CN111440154B (zh) 2020-04-24 2022-04-19 梯尔希（南京）药物研发有限公司 一种替格列汀二聚体杂质的合成方法
CN111362967B (zh) 2020-04-28 2021-09-07 南京雷正医药科技有限公司 苯并氧杂二氮杂十四碳烯衍生物及其用途
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) 2020-05-05 2023-01-01 Nuvalent Inc Macrocyclic heteroaromatic chemotherapeutic agents
BR112022022511A2 (pt) 2020-05-06 2022-12-13 Servier Lab Inibidores macrocíclicos de lrrk2 quinase
WO2021233296A1 (zh) 2020-05-18 2021-11-25 深圳市塔吉瑞生物医药有限公司 大环化合物的固体形式及其制备和用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022194399A1 (en) 2020-07-13 2022-09-22 Idorsia Pharmaceuticals Ltd Macrocycles as cftr modulators
WO2022017408A1 (zh) 2020-07-22 2022-01-27 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途
CN111808147B (zh) 2020-07-28 2023-04-18 奥来德(上海)光电材料科技有限公司 一种有机磷光材料及其制备方法和电致发光器件
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022239717A1 (en) 2021-03-15 2023-11-02 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
US20240217977A1 (en) 2021-03-31 2024-07-04 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
CN113105440B (zh) 2021-04-15 2022-10-04 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物及其制备方法和应用
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
PE20250262A1 (es) 2021-05-14 2025-01-29 Bristol Myers Squibb Co Compuestos heterociclicos sustituidos
TW202320768A (zh) 2021-10-01 2023-06-01 美商努法倫特公司 雜芳族大環醚化合物之固體形式、醫藥組成物及製備
CA3231608A1 (en) 2021-10-01 2023-04-06 Amit M. Deshpande Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
WO2023059801A1 (en) 2021-10-06 2023-04-13 The Regents Of The University Of Colorado, A Body Corporate Biomarkers for egfr-mediated resistance in oncogene-driven cancers and methods of treating, preventing, and/or ameliorating oncogene-driven cancers
WO2023179600A1 (zh) 2022-03-21 2023-09-28 杭州德睿智药科技有限公司 新型取代大杂环类新化合物及其应用
IL315520A (en) 2022-04-07 2024-11-01 Nuvalent Inc Stable Formations, Medicinal Compounds and Preparation of Heteroaromatic Macrocyclic Ether Compounds

Also Published As

Publication number Publication date
US20240317771A1 (en) 2024-09-26
AU2022357554A1 (en) 2024-04-11
CN118234725A (zh) 2024-06-21
KR20240087788A (ko) 2024-06-19
EP4408844A1 (en) 2024-08-07
MX2024003738A (es) 2024-06-19
US20230124705A1 (en) 2023-04-20
IL311444A (en) 2024-05-01
WO2023056405A1 (en) 2023-04-06
JP2024537795A (ja) 2024-10-16
US12043626B2 (en) 2024-07-23
TW202320768A (zh) 2023-06-01

Similar Documents

Publication Publication Date Title
US12043626B2 (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
US20230322797A1 (en) Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
EP2829545B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR101829595B1 (ko) 3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
KR20190003750A (ko) 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물
TWI845819B (zh) 用作激酶抑制劑的化合物及其應用
AU2017326297B2 (en) 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
WO2024086634A1 (en) Heteroaromatic macrocyclic ether chemotherapeutic agents
CN109843300B (zh) 一种化合物的结晶多晶型形式
WO2025072117A1 (en) Heteroaromatic macrocyclic ether compounds and isotopologues thereof
WO2024036097A1 (en) Heteroaromatic macrocyclic ether compounds and isotopologues thereof
EP4568969A1 (en) Heteroaromatic macrocyclic ether compounds
TW201932117A (zh) 經取代三唑衍生物之前驅藥及其用途
JP6767589B1 (ja) 化合物の塩及びそれらの結晶
WO2011088075A2 (en) Novel salts, polymorphs, and synthetic processes regarding imidazole derivative
WO2024255837A1 (zh) 一种enpp1抑制剂的晶型
WO2025117672A1 (en) Indazolyl-piperidine sulfonamides and related compounds and their use in therapy
OA16962A (fr) Nouveaux dérivés phosphates, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
HK1203196B (en) Substituted benzylpyrazoles

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241209

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20241209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250416

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250501

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250501

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250908

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250908